BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD

7.14

+0.09 (1.28%)

At close: Jul 19, 2024, 4:00 PM

7.22

+0.08 (1.12%)

Pre-market: Jul 22, 2024, 8:32 AM EDT

BioCryst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Net Income	-208.59	-226.54	-247.12	-184.06	-182.81	-108.9	Upgrade
Depreciation & Amortization	1.56	1.66	1.44	0.78	0.75	0.72	Upgrade
Share-Based Compensation	55.26	55.62	44.7	34.64	14.79	17.72	Upgrade
Other Operating Activities	50.46	74.13	39.13	6.49	32.16	0.87	Upgrade
Operating Cash Flow	-101.31	-95.14	-161.85	-142.16	-135.11	-89.58	Upgrade
Capital Expenditures	-2.24	-2.17	-1.35	-2.39	-0.51	-0.34	Upgrade
Change in Investments	6.61	-129.33	-126.89	18.19	-6.34	78.28	Upgrade
Investing Cash Flow	4.37	-131.5	-128.24	15.8	-6.86	77.93	Upgrade
Share Issuance / Repurchase	5.3	8.68	14.96	65.79	95.73	59.74	Upgrade
Debt Issued / Paid	25.59	25.98	73.07	293.87	190.05	19.48	Upgrade
Other Financing Activities	-4.52	-2.17	-	-	14.82	19.88	Upgrade
Financing Cash Flow	26.36	32.49	88.03	359.67	300.59	99.1	Upgrade
Exchange Rate Effect	0.12	0.36	0.57	0.07	0	0	Upgrade
Net Cash Flow	-70.47	-193.79	-201.5	233.39	158.63	87.45	Upgrade
Free Cash Flow	-103.56	-97.31	-163.2	-144.54	-135.62	-89.93	Upgrade
Free Cash Flow Margin	-29.14%	-29.36%	-60.26%	-91.97%	-761.41%	-184.14%	Upgrade
Free Cash Flow Per Share	-0.50	-0.51	-0.88	-0.81	-0.81	-0.78	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).